Abstract：
BACKGROUND: Some individuals may not retain adequate immunity against measles and rubella years after two doses of measles, mumps, and rubella (MMR) vaccination due to vaccine failure. This study aimed to investigate the rates of vaccine failure and seroconversion by administering an MMR booster to young adults.
METHODS: We first assessed measles and rubella antibody levels using the Luminex multiplex assay, VIDAS IgG assay, and plaque reduction neutralization test (PRNT) among individuals aged 18-30 years old who had received two doses of MMR vaccine. Participants with low measles and/or rubella antibody levels as confirmed by VIDAS received an MMR booster. Antibody levels were measured at 1-month post-booster.
RESULTS: Among 791 participants, the measles and rubella seroprevalence rates were 94.7% (95% CI: 92.9%-96.0%) and 97.3% (95% CI: 96.0%-98.3%), respectively. Lower seroprevalence rates were observed among older participants. 113 participants who received an MMR booster acquired higher measles and rubella antibody levels at 1-month post-booster compared to baseline.
CONCLUSIONS: Although measles and rubella vaccine failures were observed among 5.3% and 2.7% of young adults, respectively, an MMR booster triggered a significant antibody response.
METHODS: We first assessed measles and rubella antibody levels using the Luminex multiplex assay, VIDAS IgG assay, and plaque reduction neutralization test (PRNT) among individuals aged 18-30 years old who had received two doses of MMR vaccine. Participants with low measles and/or rubella antibody levels as confirmed by VIDAS received an MMR booster. Antibody levels were measured at 1-month post-booster.
RESULTS: Among 791 participants, the measles and rubella seroprevalence rates were 94.7% (95% CI: 92.9%-96.0%) and 97.3% (95% CI: 96.0%-98.3%), respectively. Lower seroprevalence rates were observed among older participants. 113 participants who received an MMR booster acquired higher measles and rubella antibody levels at 1-month post-booster compared to baseline.
CONCLUSIONS: Although measles and rubella vaccine failures were observed among 5.3% and 2.7% of young adults, respectively, an MMR booster triggered a significant antibody response.
摘要：
背景：有些人在服用两剂麻疹后可能无法保持对麻疹和风疹的足够免疫力，腮腺炎,和风疹（MMR）疫苗接种由于疫苗失败。这项研究旨在通过向年轻人施用MMR加强剂来调查疫苗失败和血清转化率。
方法：我们首先使用Luminex多重检测方法评估麻疹和风疹抗体水平，VIDASIgG测定，以及接受两剂MMR疫苗的18-30岁个体的斑块减少中和试验（PRNT）。经VIDAS证实，麻疹和/或风疹抗体水平低的参与者接受了MMR加强剂。在加强后1个月测量抗体水平。
结果：在791名参与者中，麻疹和风疹血清阳性率分别为94.7%(95%CI:92.9%-96.0%)和97.3%(95%CI:96.0%-98.3%),分别。在老年参与者中观察到较低的血清阳性率。与基线相比，113名接受MMR加强的参与者在加强后1个月获得了更高的麻疹和风疹抗体水平。
结论：尽管在5.3％和2.7％的年轻人中观察到麻疹和风疹疫苗失败，分别,MMR加强剂触发了显著的抗体反应。
方法：我们首先使用Luminex多重检测方法评估麻疹和风疹抗体水平，VIDASIgG测定，以及接受两剂MMR疫苗的18-30岁个体的斑块减少中和试验（PRNT）。经VIDAS证实，麻疹和/或风疹抗体水平低的参与者接受了MMR加强剂。在加强后1个月测量抗体水平。
结果：在791名参与者中，麻疹和风疹血清阳性率分别为94.7%(95%CI:92.9%-96.0%)和97.3%(95%CI:96.0%-98.3%),分别。在老年参与者中观察到较低的血清阳性率。与基线相比，113名接受MMR加强的参与者在加强后1个月获得了更高的麻疹和风疹抗体水平。
结论：尽管在5.3％和2.7％的年轻人中观察到麻疹和风疹疫苗失败，分别,MMR加强剂触发了显著的抗体反应。
